UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053447
Receipt number R000060878
Scientific Title A study to evaluate the effects of consumption of the test beverage on sleep quality
Date of disclosure of the study information 2024/01/26
Last modified on 2024/01/12 14:58:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate the effects of consumption of the test beverage on sleep quality

Acronym

A study to evaluate the effects of consumption of the test beverage on sleep quality

Scientific Title

A study to evaluate the effects of consumption of the test beverage on sleep quality

Scientific Title:Acronym

A study to evaluate the effects of consumption of the test beverage on sleep quality

Region

Japan


Condition

Condition

Healthy volunteers

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effects of consumption of the test beverage on sleep quality

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

OSA sleep inventory MA version

Key secondary outcomes

St. Mary's Hospital Sleep Questionnaire, activity tracker


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Consumption of test food for two week (one bottle a day)

Interventions/Control_2

Consumption of placebo for two week (one bottle a day)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1) Males and females whose age of 20 years or more and less than 65 years
2) Subjects who have complaints for sleep
3) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent

Key exclusion criteria

1) Subjects receiving a medical treatment for sleep disorders
2) Subjects receiving a medical treatment for serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders
3) Subjects receiving a medical treatment for chronic diseases such as diabetes, hypertension and dyslipidemia
4) Subjects whose lifestyles are irregular because of night shift or others
5) Subjects having some problems in nocturnal sleep occurred from past irregular shift work
6) Subjects waking up for urination 2 times or more during nocturnal sleep
7) Subjects living with their infants less than 1 year old
8) Subjects sleeping with others in the same bedroom
9) Subjects drinking a lot (Subjects whose pure alcohol intake per day is 60 g or more)
10) Subjects regularly taking medicines and quasi-drugs having the effects on sleep quality
11) Subjects regularly taking Food with Functional Claims having the effects on sleep quality
12) Subjects who have severe allergic rhinitis.
13) Subjects having the possibility of developing allergic symptoms by the test food
14) Female subjects who are pregnant or lactating, or intending to become pregnant during the study
15) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study
16) Subjects deemed unsuitable by the investigator

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Hiroshi
Middle name
Last name Ishimoto

Organization

Ezaki Glico Co., Ltd.

Division name

Applied Research Laboratory

Zip code

555-8502

Address

4-6-5, Utajima, Nishiyodogawa-ku, Osaka-shi, Osaka

TEL

050-1751-2061

Email

hiroshi.ishimoto@glico.com


Public contact

Name of contact person

1st name Tomohiro
Middle name
Last name Sugino

Organization

Soiken Inc.

Division name

R&D Division

Zip code

560-0082

Address

Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka-shi, Osaka

TEL

06-6871-8888

Homepage URL


Email

sugino@soiken.com


Sponsor or person

Institute

Ezaki Glico Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Fukuda Clinic

Address

Shin-Osaka brick building 2F, 1-6- 1 Miyahara, Yodogawa-ku, Osaka-shi, Osaka

Tel

06-6398-0203

Email

fukudaclinicIRB@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 12 Month 16 Day

Date of IRB

2023 Year 12 Month 16 Day

Anticipated trial start date

2024 Year 02 Month 24 Day

Last follow-up date

2024 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 01 Month 26 Day

Last modified on

2024 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060878


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name